Cover Image
市場調查報告書

白細胞介素2 (T細胞生長因子或Aldesleukin或IL2) :開發中產品分析

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 364830
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
白細胞介素2 (T細胞生長因子或Aldesleukin或IL2) :開發中產品分析 Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016
出版日期: 2016年11月09日 內容資訊: 英文 64 Pages
簡介

本報告提供以白細胞介素2 (T細胞生長因子或Aldesleukin或IL2) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

白細胞介素2 (T細胞生長因子或Aldesleukin或IL2)的概要

治療藥的開發

白細胞介素2 (T細胞生長因子或Aldesleukin或IL2):開發中的產品 - 各開發階段

白細胞介素2 (T細胞生長因子或Aldesleukin或IL2):開發中的產品 - 各治療範圍

白細胞介素2 (T細胞生長因子或Aldesleukin或IL2):開發中的產品 - 各適應症

白細胞介素2 (T細胞生長因子或Aldesleukin或IL2):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

白細胞介素2 (T細胞生長因子或Aldesleukin或IL2):企業開發中的產品

白細胞介素2 (T細胞生長因子或Aldesleukin或IL2):大學/機關開發中的產品

白細胞介素2 (T細胞生長因子或Aldesleukin或IL2):治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

白細胞介素2 (T細胞生長因子或Aldesleukin或IL2)的治療藥開發企業

  • Alkermes Plc
  • Biomar Microbial Technologies
  • Cyxone AB
  • OncBioMune Pharmaceuticals Inc.
  • Transgene SA
  • ZIOPHARM Oncology, Inc.

藥物簡介

白細胞介素2 (T細胞生長因子或Aldesleukin或IL2):暫停中的計劃

白細胞介素2 (T細胞生長因子或Aldesleukin或IL2):開發中止的產品

白細胞介素2 (T細胞生長因子或Aldesleukin或IL2):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0647TDB

Summary

Global Markets Direct's, 'Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2)
  • The report reviews Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Overview 7
  • Therapeutics Development 8
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Stage of Development 8
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Therapy Area 9
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Indication 10
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Products Glance 11
  • Late Stage Products 11
  • Early Stage Products 12
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Companies 13
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Universities/Institutes 15
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Therapeutics Assessment 17
  • Assessment by Monotherapy/Combination Products 17
  • Assessment by Mechanism of Action 18
  • Assessment by Route of Administration 20
  • Assessment by Molecule Type 22
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Companies Involved in Therapeutics Development 24
  • Alkermes Plc 24
  • Biomar Microbial Technologies 25
  • Cyxone AB 26
  • OncBioMune Pharmaceuticals Inc. 27
  • Transgene SA 28
  • ZIOPHARM Oncology, Inc. 29
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Drug Profiles 30
  • ALKS-4230 - Drug Profile 30
  • Product Description 30
  • Mechanism Of Action 30
  • R&D Progress 30
  • Anti-PD1 Antibody + TILT-123 - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile 32
  • Product Description 32
  • Mechanism Of Action 32
  • R&D Progress 32
  • BNZ-1 - Drug Profile 33
  • Product Description 33
  • Mechanism Of Action 33
  • R&D Progress 33
  • Chimeric Antigen Receptor T Cell + TILT-123 - Drug Profile 34
  • Product Description 34
  • Mechanism Of Action 34
  • R&D Progress 34
  • IB-08C175 - Drug Profile 35
  • Product Description 35
  • Mechanism Of Action 35
  • R&D Progress 35
  • Prostatac - Drug Profile 36
  • Product Description 36
  • Mechanism Of Action 36
  • R&D Progress 36
  • T-20K - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • TG-4010 - Drug Profile 40
  • Product Description 40
  • Mechanism Of Action 40
  • R&D Progress 40
  • TILT-123 + Tumor Infiltrating Lymphocytes - Drug Profile 44
  • Product Description 44
  • Mechanism Of Action 44
  • R&D Progress 44
  • Vaccine to Target CD80 and IL-2 for Acute Myeloblastic Leukemia - Drug Profile 45
  • Product Description 45
  • Mechanism Of Action 45
  • R&D Progress 45
  • Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile 46
  • Product Description 46
  • Mechanism Of Action 46
  • R&D Progress 46
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Dormant Projects 47
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Discontinued Products 50
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Featured News & Press Releases 51
  • Oct 24, 2016: Immunotherapy Expert Dr. Brian Barnett Joins OncBioMune Scientific Advisory Board 51
  • Oct 19, 2016: OncBioMune Receives Notice of Patent Allowance for Novel Cancer Vaccine ProscaVax in Mexico 51
  • Sep 26, 2016: OncBioMune CEO Dr. Jonathan Head to Present Abstract on Prostate Cancer Vaccine at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival 52
  • Aug 08, 2016: Latest Data From Phase 1 Trial of ProscaVax for Prostate Cancer Reinforces Safety and Benefit of Novel Cancer Vaccine 52
  • Jul 20, 2016: Pre-Clinical Research Supports Additional Studies of OncBioMune Technology for Breast Cancer Vaccine 53
  • Jul 13, 2016: OncBioMune Submits Protocol to Initiate Phase 2/3 Trial of ProscaVax for Prostate Cancer 54
  • Jun 14, 2016: OncBioMune Provides Corporate Update; ASCO Reinforces Market Opportunity for New Prostate Cancer Vaccine as Phase 2 Trial Approaches 54
  • Jun 02, 2016: Mexican Regulatory Authorities Supportive of OncBioMunes Phase 2 of ProscaVax for Prostate Cancer 56
  • May 25, 2016: Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 57
  • May 18, 2016: Doctors Voice Optimism About Phase 2 Trial of ProscaVax in Mexico for Prostate Cancer 57
  • May 11, 2016: OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer 58
  • May 04, 2016: OncBioMune Submits Protocol to Principal Investigators for Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer 59
  • Apr 28, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in China 60
  • Apr 12, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Hong Kong 61
  • Mar 29, 2016: Multiple sclerosis: plant peptide could prevent onset of the disease 61
  • Appendix 63
  • Methodology 63
  • Coverage 63
  • Secondary Research 63
  • Primary Research 63
  • Expert Panel Validation 63
  • Contact Us 63
  • Disclaimer 64

List of Tables

  • Number of Products under Development for, H2 2016 8
  • Number of Products under Development by Therapy Area, H2 2016 9
  • Number of Products under Development by Indication, H2 2016 10
  • Comparative Analysis by Late Stage Development, H2 2016 11
  • Comparative Analysis by Early Stage Products, H2 2016 12
  • Number of Products under Development by Companies, H2 2016 13
  • Products under Development by Companies, H2 2016 14
  • Number of Products under Investigation by Universities/Institutes, H2 2016 15
  • Products under Investigation by Universities/Institutes, H2 2016 16
  • Assessment by Monotherapy/Combination Products, H2 2016 17
  • Number of Products by Stage and Mechanism of Action, H2 2016 19
  • Number of Products by Stage and Route of Administration, H2 2016 21
  • Number of Products by Stage and Molecule Type, H2 2016 23
  • Pipeline by Alkermes Plc, H2 2016 24
  • Pipeline by Biomar Microbial Technologies, H2 2016 25
  • Pipeline by Cyxone AB, H2 2016 26
  • Pipeline by OncBioMune Pharmaceuticals Inc., H2 2016 27
  • Pipeline by Transgene SA, H2 2016 28
  • Pipeline by ZIOPHARM Oncology, Inc., H2 2016 29
  • Dormant Projects, H2 2016 47
  • Dormant Projects (Contd..1), H2 2016 48
  • Dormant Projects (Contd..2), H2 2016 49
  • Discontinued Products, H2 2016 50

List of Figures

  • Number of Products under Development for, H2 2016 8
  • Number of Products under Development by Therapy Area, H2 2016 9
  • Number of Products under Development by Top 10 Indication, H2 2016 10
  • Comparative Analysis by Late Stage Development, H2 2016 11
  • Comparative Analysis by Early Stage Products, H2 2016 12
  • Assessment by Monotherapy/Combination Products, H2 2016 17
  • Number of Products by Mechanism of Actions, H2 2016 18
  • Number of Products by Stage and Mechanism of Actions, H2 2016 18
  • Number of Products by Routes of Administration, H2 2016 20
  • Number of Products by Stage and Routes of Administration, H2 2016 20
  • Number of Products by Molecule Types, H2 2016 22
  • Number of Products by Stage and Molecule Type, H2 2016 22
Back to Top